Mycobacterial subversion of chemotherapeutic reagents and host defense tactics: Challenges in tuberculosis drug development

Annual Review of Pharmacology and Toxicology

Volumn 49, Issue , 2009, Pages 427-453

  Nguyen, Liem ^a   Pieters, Jean ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antibiotic resistance; Macrophage; Mycobacteria; Phagosome maturation; Phagosome lysosome fusion; Tuberculosis

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEPHALOSPORINASE; CIPROFLOXACIN; CLARITHROMYCIN; DIBEKACIN; GENTAMICIN; KHELLIN; LEVOFLOXACIN; LINCOSAMIDE; MACROLIDE; METHYLGLYOXAL; MYCOBACTERIUM ANTIGEN; NETILMICIN; NITRIC OXIDE; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PROTEIN KINASE; RIFAMPICIN; RIFAMYCIN; TOBRAMYCIN; TOLL LIKE RECEPTOR; UBIQUITIN; VANCOMYCIN; VITAMIN D; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AUTOPHAGY; BIOSYNTHESIS; DRUG ACTIVITY; DRUG DEGRADATION; DRUG TOLERANCE; HOST RESISTANCE; MULTIDRUG RESISTANCE; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERMEABILITY BARRIER; PHAGOCYTOSIS; PHAGOLYSOSOME; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; REVIEW; TUBERCULOSIS; ANIMAL; CHEMICAL STRUCTURE; DRUG DESIGN; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; HUMAN; MICROBIAL VIABILITY;

CORYNEBACTERINEAE; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; HOST-PATHOGEN INTERACTIONS; HUMANS; MICROBIAL VIABILITY; MODELS, MOLECULAR; MYCOBACTERIUM TUBERCULOSIS;

EID: 65249188733     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-061008-103123     Document Type: Review

References (133)

1. Myers A. 1963. Can tuberculosis be eradicated? Chest 43:327-29
2. Goldman RC, Plumley KV, Laughon BE. 2007. The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control. Infect. Disord. Drug Targets 7:73-91
3. Nguyen L, Thompson CJ. 2006. Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. Trends Microbiol. 14:304-12
4. Armstrong JA, Hart DPA. 1971. Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J. Exp. Med. 134:713-40
5. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. 2005. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob. Agents Chemother. 49:2816-21
6. Brennan PJ, Nikaido H. 1995. The envelope of mycobacteria. Annu. Rev. Biochem. 64:29-63
7. Liu J, Nikaido H. 1999. A mutant of Mycobacterium smegmatis defective in the biosynthesis of mycolic acids accumulates meromycolates. Proc. Natl. Acad. Sci. USA 96:4011-16
8. Philalay JS, Palermo CO, Hauge KA, Rustad TR, Cangelosi GA. 2004. Genes required for intrinsic multidrug resistance in Mycobacterium avium. Antimicrob. Agents Chemother. 48:3412-18
9. Gao LY, Laval F, Lawson EH, Groger RK, Woodruff A, et al. 2003. Requirement for kasB in Mycobacterium mycolic acid biosynthesis, cell wall impermeability and intracellular survival: implications for therapy. Mol. Microbiol. 49:1547-63
10. Singh A, Jain S, Gupta S, Das T,Tyagi AK. 2003.mymAoperon of Mycobacterium tuberculosis: its regulation and importance in the cell envelope. FEMS Microbiol. Lett. 227:53-63
11. Singh A, Gupta R, Vishwakarma RA, Narayanan PR, Paramasivan CN, et al. 2005. Requirement of the mymA operon for appropriate cell wall ultrastructure and persistence of Mycobacterium tuberculosis in the spleens of guinea pigs. J. Bacteriol. 187:4173-86
12. Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, Besra GS. 1997. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276:1420-22
13. Nguyen L, Chinnapapagari S, Thompson CJ. 2005. FbpA-Dependent biosynthesis of trehalose dimycolate is required for the intrinsic multidrug resistance, cell wall structure, and colonial morphology of Mycobacterium smegmatis. J. Bacteriol. 187:6603-11
14. Niederweis M. 2003. Mycobacterial porins - new channel proteins in unique outer membranes. Mol. Microbiol. 49:1167-77
15. Stephan J, Mailaender C, Etienne G, Daffe M, Niederweis M. 2004. Multidrug resistance of a porin deletion mutant of Mycobacterium smegmatis. Antimicrob. Agents Chemother. 48:4163-70
16. De Rossi E, Ainsa JA, Riccardi G. 2006. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol. Rev. 30:36-52
17. Viveiros M, Leandro C, Amaral L. 2003. Mycobacterial efflux pumps and chemotherapeutic implications. Int. J. Antimicrob. Agents 22:274-78
18. Nikaido H. 1994. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 264:382-88
19. Chambers HF,Moreau D,Yajko D, Miick C,Wagner C, et al. 1995. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob. Agents Chemother. 39:2620-24
20. Flores AR, Parsons LM, PavelkaMSJr. 2005. Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to beta-lactam antibiotics. Microbiology 151:521-32
21. Ainsa JA, Martin C, Gicquel B, Gomez-Lus R. 1996. Characterization of the chromosomal aminoglycoside 2′-N-acetyltransferase gene from Mycobacterium fortuitum. Antimicrob. Agents Chemother. 40:2350-55
22. Vetting M, Roderick SL, Hegde S, Magnet S, Blanchard JS. 2003. What can structure tell us about in vivo function? The case of aminoglycoside-resistance genes. Biochem. Soc. Trans. 31:520-22
23. Dabbs ER, Quan S. 2000. Light inhibits rifampicin inactivation and reduces rifampicin resistance due to a cloned mycobacterial ADP-ribosylation gene. FEMS Microbiol. Lett. 182:105-19
24. Alexander DC, Jones JR, Liu J. 2003. A rifampin-hypersensitive mutant reveals differences between strains of Mycobacterium smegmatis and presence of a novel transposon, IS1623. Antimicrob. Agents Chemother. 47:3208-13
25. Rawat M, Newton GL, Ko M, Martinez GJ, Fahey RC, Av-Gay Y. 2002. Mycothiol-deficient Mycobacterium smegmatis mutants are hypersensitive to alkylating agents, free radicals, and antibiotics. Antimicrob. Agents Chemother. 46:3348-55
26. Buchmeier NA, Newton GL, Koledin T, Fahey RC. 2003. Association of mycothiol with protection of Mycobacterium tuberculosis from toxic oxidants and antibiotics. Mol. Microbiol. 47:1723-32
27. Buriankova K, Doucet-Populaire F, Dorson O, Gondran A, Ghnassia JC, et al. 2004. Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex. Antimicrob. Agents Chemother. 48:143-50
28. Nash KA. 2003. Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38). Antimicrob. Agents Chemother. 47:3053-60
29. Nash KA, Zhang Y, Brown-Elliott BA, Wallace RJ Jr. 2005. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J. Antimicrob. Chemother. 55:170-77
30. Duncan K, Barry CE 3rd. 2004. Prospects for new antitubercular drugs. Curr. Opin. Microbiol. 7:460-65
31. De Souza MV, Vasconcelos TR, de Almeida MV, Cardoso SH. 2006. Fluoroquinolones: an important class of antibiotics against tuberculosis. Curr. Med. Chem. 13:455-63
32. Andriole VT. 2005. The quinolones: past, present, and future. Clin. Infect. Dis. 41(Suppl. 2):S113-19
33. Montero C, Mateu G, Rodriguez R, Takiff H. 2001. Intrinsic resistance of Mycobacterium smegmatis to fluoroquinolones may be influenced by new pentapeptide protein MfpA. Antimicrob. Agents Chemother. 45:3387-92
34. Hegde SS, Vetting MW, Roderick SL, Mitchenall LA, Maxwell A, et al. 2005. A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science 308:1480-83
35. Ferber D. 2005. Biochemistry. Protein that mimics DNA helps tuberculosis bacteria resist antibiotics. Science 308:1393
36. Morais Cabral JH, Jackson AP, Smith CV, Shikotra N, Maxwell A, Liddington RC. 1997. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 388:903-6
37. Chen JM, Ren H, Shaw JE, Wang YJ, Li M, et al. 2008. Lsr2 of Mycobacterium tuberculosis is a DNA-bridging protein. Nucleic Acids Res. 36:2123-35
38. Frenkiel-Krispin D, Levin-Zaidman S, Shimoni E, Wolf SG, Wachtel EJ, et al. 2001. Regulated phase transitions of bacterial chromatin: a nonenzymatic pathway for generic DNA protection. EMBO J. 20:1184-91
39. Colangeli R, Helb D, Sridharan S, Sun J, Varma-Basil M, et al. 2005. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol. Microbiol. 55:1829-40
40. Colangeli R, Helb D, Vilcheze C, Hazbon MH, Lee CG, et al. 2007. Transcriptional regulation of multi-drug tolerance and antibiotic-induced responses by the histone-like protein Lsr2 in M. tuberculosis. PLoS Pathog. 3:e87
41. Davis NK, Chater KF. 1992. The Streptomyces coelicolor whiB gene encodes a small transcription factor-like protein dispensable for growth but essential for sporulation. Mol. Gen. Genet. 232:351-58
42. Gomez JE, Bishai WR. 2000. whmD is an essential mycobacterial gene required for proper septation and cell division. Proc. Natl. Acad. Sci. USA 97:8554-59
43. Steyn AJ, Collins DM, Hondalus MK, Jacobs WR Jr, Kawakami RP, Bloom BR. 2002. Mycobacterium tuberculosis WhiB3 interacts with RpoV to affect host survival but is dispensable for in vivo growth. Proc. Natl. Acad. Sci. USA 99:3147-52
44. Morris RP, Nguyen L, Gatfield J, Visconti K, Nguyen K, et al. 2005. Ancestral antibiotic resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 102:12200-5
45. Ainsa JA, Blokpoel MC, Otal I, Young DB, De Smet KA, Martin C. 1998. Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J. Bacteriol. 180:5836-43
46. Rohde K, Yates RM, Purdy GE, Russell DG. 2007. Mycobacterium tuberculosis and the environment within the phagosome. Immunol. Rev. 219:37-54
47. Wei J, Dahl JL, Moulder JW, Roberts EA, O'Gaora P, et al. 2000. Identification of a Mycobacterium tuberculosis gene that enhances mycobacterial survival in macrophages. J. Bacteriol. 182:377-84
48. Samuel LP, Song CH, Wei J, Roberts EA, Dahl JL, et al. 2007. Expression, production and release of the Eis protein by Mycobacterium tuberculosis during infection of macrophages and its effect on cytokine secretion. Microbiology 153:529-40
49. Lella RK, Sharma C. 2007. Eis (enhanced intracellular survival) protein of Mycobacterium tuberculosis disturbs the cross regulation of T-cells. J. Biol. Chem. 282:18671-75
50. Gold B, Rodriguez GM, Marras SA, Pentecost M, Smith I. 2001. The Mycobacterium tuberculosis IdeR is a dual functional regulator that controls transcription of genes involved in iron acquisition, iron storage and survival in macrophages. Mol. Microbiol. 42:851-65
51. Ratledge C. 2004. Iron, mycobacteria and tuberculosis. Tuberculosis 84:110-30
52. Geiman DE, Raghunand TR, Agarwal N, Bishai WR. 2006. Differential gene expression in response to exposure to antimycobacterial agents and other stress conditions among seven Mycobacterium tuberculosis whiB-like genes. Antimicrob. Agents Chemother. 50:2836-41
53. Zimmerli S, Edwards S, Ernst JD. 1996. Selective receptor blockade during phagocytosis does not alter the survival and growth of Mycobacterium tuberculosis in human macrophages. Am. J. Respir. Cell Mol. Biol. 15:760-70
54. Ernst JD. 1998. Macrophage receptors for Mycobacterium tuberculosis. Infect. Immun. 66:1277-81
55. Peyron P, Bordier C, N'Diaye EN, Maridonneau-Parini I. 2000. Nonopsonic phagocytosis of Mycobacterium kansasii by human neutrophils depends on cholesterol and is mediated by CR3 associated with glycosylphosphatidylinositol- anchored proteins. J. Immunol. 165:5186-91
56. Velasco-Velázquez MA, Barrera D, González-Arenas A, Rosales C, Agramonte-Hevia J. 2003. Macrophage-Mycobacterium tuberculosis interactions: role of complement receptor 3. Microb. Pathog. 35:125-31
57. Ferguson JS,Weis JJ, Martin JL, Schlesinger LS. 2004. Complement proteinC3binding to Mycobacterium tuberculosis is initiated by the classical pathway in human bronchoalveolar lavage fluid. Infect. Immun. 72:2564-73
58. Gatfield J, Pieters J. 2000. Essential role for cholesterol in entry of mycobacteria into macrophages. Science 288:1647-50
59. Vasanji A, Ghosh PK, Graham LM, Eppell SJ, Fox PL. 2004. Polarization of plasma membrane microviscosity during endothelial cell migration. Dev. Cell 6:29-41
60. Ferrari G, Langen H, Naito M, Pieters J. 1999.Acoat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell 97:435-47
61. de Chastellier C, Thilo L. 2006. Cholesterol depletion in Mycobacterium avium-infected macrophages overcomes the block in phagosome maturation and leads to the reversible sequestration of viable mycobacteria in phagolysosome-derived autophagic vacuoles. Cell Microbiol. 8:242-56
62. Tailleux L, Neyrolles O, Honoré-Bouakline S, Perret E, Sanchez F, et al. 2003. Constrained intracellular survival of Mycobacterium tuberculosis in human dendritic cells. J. Immunol. 170:1939-48
63. Pieters J. 2008. Coronin 1 and innate immunity. In The Coronin Family of Proteins, ed. C Clemen, L Eichinger, V Rybakin, pp. 116-23. New York: Landes Biosci./Springer Sci.
64. de Hostos EL. 1999. The coronin family of actin-associated proteins. Trends Cell Biol. 9:345-50
65. Jayachandran R, Gatfield J, Massner J, Albrecht I, Zanolari B, Pieters J. 2008. RNA interference in J774 macrophages reveals a role for Coronin 1 in Mycobacterial trafficking but not in actin-dependent processes. Mol. Biol. Cell 19:1241-51
66. Jayachandran R, Sundaramurthy V, Combaluzier B, Mueller P, Korf H, et al. 2007. Survival of mycobacteria in macrophages is mediated by coronin 1-dependent activation of calcineurin. Cell 130:37-50
67. Mueller P, Massner J, Jayachandran R, Combaluzier B, Albrecht I, et al. 2008. Regulation ofTcell survival through coronin-1-mediated generation of inositol-1,4,5-trisphosphate and calcium mobilization after T cell receptor triggering. Nat. Immunol. 9:424-31
68. Kang YJ, Kusler B, Otsuka M, Hughes M, Suzuki N, et al. 2007. Calcineurin negatively regulates TLR-mediated activation pathways. J. Immunol. 179:4598-607
69. Deghmane AE, Soulhine H, Bach H, Sendide K, Itoh S, et al. 2007. Lipoamide dehydrogenase mediates retention of coronin-1 onBCGvacuoles, leading to arrest in phagosomematuration. J. Cell Sci. 120:2796-806
70. Vergne I, Chua J, Deretic V. 2003. Mycobacterium tuberculosis phagosome maturation arrest: selective targeting of PI3P-dependent membrane trafficking. Traffic 4:600-6
71. Chua J, Vergne I, Master S, Deretic V. 2004. A tale of two lipids: Mycobacterium tuberculosis phagosome maturation arrest. Curr. Opin. Microbiol. 7:71-77
72. Fratti RA, Chua J,Vergne I, Deretic V. 2003. Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc. Natl. Acad. Sci. USA 100:5437-42
73. Sturgill-Koszycki S, Schaible UE, Russell DG. 1996. Mycobacterium-containing phagosomes are accessible to early endosomes and reflect a transitional state in normal phagosome biogenesis. EMBO J. 15:6960-68
74. Vergne I, Chua J, Lee HH, Lucas M, Belisle J, Deretic V. 2005. Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 102:4033-38
75. Yang CS, Lee JS, Song CH, Hur GM, Lee SJ, et al. 2007. Protein kinase C zeta plays an essential role for Mycobacterium tuberculosis-induced extracellular signal-regulated kinase 1/2 activation in monocytes/macrophages via Toll-like receptor 2. Cell Microbiol. 9:382-96
76. St-Denis A, Caouras V, Gervais F, Descoteaux A. 1999. Role of protein kinase C-alpha in the control of infection by intracellular pathogens in macrophages. J. Immunol. 163:5505-11
77. Kuijl C, Savage ND, Marsman M, Tuin AW, Janssen L, et al. 2007. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature 450:725-30
78. Av-Gay Y, Everett M. 2000. The eukaryotic-like Ser/Thr protein kinases of Mycobacterium tuberculosis. Trends Microbiol. 8:238-44
79. Walburger A, Koul A, Ferrari G, Nguyen L, Prescianotto-Baschong C, et al. 2004. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science 304:1800-4
80. Abdallah AM, Verboom T, Hannes F, Safi M, Strong M, et al. 2006. A specific secretion system mediates PPE41 transport in pathogenic mycobacteria. Mol. Microbiol. 62:667-79
81. Champion PA, Stanley SA, Champion MM, Brown EJ, Cox JS. 2006. C-terminal signal sequence promotes virulence factor secretion in Mycobacterium tuberculosis. Science 313:1632-36
82. Gey van Pittius NC, Gamieldien J, Hide W, Brown GD, Siezen RJ, Beyers AD. 2001. The ESAT-6 gene cluster of Mycobacterium tuberculosis and other high G+C Gram-positive bacteria. Genome Biol. 2:RESEARCH0044
83. Teitelbaum R, Cammer M, Maitland ML, Freitag NE, Condeelis J, Bloom BR. 1999. Mycobacterial infection of macrophages results in membrane-permeable phagosomes. Proc. Natl. Acad. Sci. USA 96:15190-95
84. Scherr N, Honnappa S, Kunz G, Mueller P, Jayachandran R, et al. 2007. Structural basis for the specific inhibition of protein kinase G, a virulence factor of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 104:12151-56
85. MacMicking JD. 2005. Immune control of phagosomal bacteria by p47 GTPases. Curr. Opin. Microbiol. 8:74-82
86. Schoenborn JR,Wilson CB. 2007. Regulation of interferon-gamma during innate and adaptive immune responses. Adv. Immunol. 96:41-101
87. Boehm U, Klamp T, Groot M, Howard JC. 1997. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15:749-95
88. Jouanguy E, Altare F, Lamhamedi-Cherradi S, Casanova JL. 1997. Infections in IFNGR-1-deficient children. J. Interf. Cytokine Res. 17:583-87
89. Taylor GA, Feng CG, Sher A. 2004. p47 GTPases: regulators of immunity to intracellular pathogens. Nat. Rev. Immunol. 4:100-9
90. Martens S, Sabel K, Lange R, Uthaiah R, Wolf E, Howard JC. 2004. Mechanisms regulating the positioning of mouse p47 resistance GTPases LRG-47 and IIGP1 on cellular membranes: retargeting to plasma membrane induced by phagocytosis. J. Immunol. 173:2594-606
91. MacMicking JD, Taylor GA, McKinney JD. 2003. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 302:654-59
92. Feng CG, Collazo-Custodio CM, Eckhaus M, Hieny S, Belkaid Y, et al. 2004. Mice deficient in LRG-47 display increased susceptibility to mycobacterial infection associated with the induction of lymphopenia. J. Immunol. 172:1163-68
93. Levine B, Klionsky DJ. 2004. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev. Cell 6:463-77
94. Ogawa M, Yoshimori T, Suzuki T, Sagara H, Mizushima N, Sasakawa C. 2005. Escape of intracellular Shigella from autophagy. Science 307:727-31
95. Nakagawa I, Amano A, Mizushima N, Yamamoto A, Yamaguchi H, et al. 2004. Autophagy defends cells against invading group A Streptococcus. Science 306:1037-40
96. Gutierrez MG,Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. 2004. Autophagy is a defense mechanism inhibitingBCGand Mycobacterium tuberculosis survival in infected macrophages. Cell 119:753-66
97. Levine B, Kroemer G. 2008. Autophagy in the pathogenesis of disease. Cell 132:27-42
98. Kihara A, Noda T, Ishihara N, Ohsumi Y. 2001. Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase Y sorting in Saccharomyces cerevisiae. J. Cell Biol. 152:519-30
99. Van der Wel N, Hava D, Houben D, Fluitsma D, van Zon M, et al. 2007. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 129:1287-98
100. Alonso S, Pethe K, Russell DG, Purdy GE. 2007. Lysosomal killing of Mycobacterium mediated by ubiquitin-derived peptides is enhanced by autophagy. Proc. Natl. Acad. Sci. USA 104:6031-36
101. Goldberg AL. 2003. Protein degradation and protection against misfolded or damaged proteins. Nature 426:895-99
102. Takeda K, Kaisho T, Akira S. 2003. Toll-like receptors. Annu. Rev. Immunol. 21:335-76
103. Blander JM,Medzhitov R. 2004. Regulation of phagosome maturation by signals from toll-like receptors. Science 304:1014-18
104. Doyle SE, O'Connell RM, Miranda GA, Vaidya SA, Chow EK, et al. 2004. Toll-like receptors induce a phagocytic gene program through p38. J. Exp. Med. 199:81-90
105. Shiratsuchi A,Watanabe I,Takeuchi O, Akira S, Nakanishi Y. 2004. Inhibitory effect ofToll-like receptor 4 on fusion between phagosomes and endosomes/lysosomes in macrophages. J. Immunol. 172:2039-47
106. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, et al. 2006. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770-73
107. Cooper RA. 1984. Metabolism of methylglyoxal in microorganisms. Annu. Rev. Microbiol. 38:49-68
108. Li SY, Sigmon VK, Babcock SA, Ren J. 2007. Advanced glycation endproduct inducesROSaccumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes. Life Sci. 80:1051-56
109. Rachman H, Kim N, Ulrichs T, Baumann S, Pradl L, et al. 2006. Critical role of methylglyoxal and AGE in mycobacteria-induced macrophage apoptosis and activation. PLoS ONE 1:e29
110. Leong AS,Wannakrairot P, Leong TY. 2008. Apoptosis is a major cause of so-called 'Caseous Necrosis' in mycobacterial granulomas in HIV-infected patients. J. Clin. Pathol. 61:366-72
111. MacMicking J, Xie QW, Nathan C. 1997. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15:323-50
112. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. 1997. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl. Acad. Sci. USA 94:5243-48
113. Chan J, Tanaka K, Carroll D, Flynn J, Bloom BR. 1995. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect. Immun. 63:736-40
114. Botha T, Ryffel B. 2002. Reactivation of latent tuberculosis by an inhibitor of inducible nitric oxide synthase in an aerosol murine model. Immunology 107:350-57
115. Nathan C, Xie QW. 1994. Regulation of biosynthesis of nitric oxide. J. Biol. Chem. 269:13725-28
116. Flynn JL, Chan J,Triebold KJ, Dalton DK, StewartTA, Bloom BR. 1993. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:2249-54
117. Miller BH, Fratti RA, Poschet JF, Timmins GS, Master SS, et al. 2004. Mycobacteria inhibit nitric oxide synthase recruitment to phagosomes during macrophage infection. Infect. Immun. 72:2872-78
118. 2 and nitric oxide via its [4Fe-4S] cluster and is essential for nutrient starvation survival. Proc. Natl. Acad. Sci. USA 104:11562-67
119. Jayakumar D, Jacobs WR Jr, Narayanan S. 2008. Protein kinase E of Mycobacterium tuberculosis has a role in the nitric oxide stress response and apoptosis in a human macrophage model of infection. Cell Microbiol. 10:365-74
120. Darwin KH, Ehrt S, Gutierrez-Ramos JC,Weich N, Nathan CF. 2003. The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science 302:1963-66
121. Baumeister W, Walz J, Zuhl F, Seemuller E. 1998. The proteasome: paradigm of a self-compartmentalizing protease. Cell 92:367-80
122. Pieters J, Ploegh H. 2003. Microbiology. Chemical warfare and mycobacterial defense. Science 302:1900-2
123. Gandotra S, Schnappinger D, MonteleoneM, HillenW,Ehrt S. 2007. In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice. Nat. Med. 13:1515-20
124. Pearce MJ, Arora P, Festa RA, Butler-Wu SM,Gokhale RS, DarwinKH.2006. Identification of substrates of the Mycobacterium tuberculosis proteasome. EMBO J. 25:5423-32
125. McDonough KA, Kress Y, Bloom BR. 1993. Pathogenesis of tuberculosis: interaction of Mycobacterium tuberculosis with macrophages. Infect. Immun. 61:2763-73
126. Stamm LM,Morisaki JH, Gao LY, Jeng RL, McDonald KL, et al. 2003. Mycobacterium marinum escapes from phagosomes and is propelled by actin-based motility. J. Exp. Med. 198:1361-68
127. Tan T, Lee WL, Alexander DC, Grinstein S, Liu J. 2006. The ESAT-6/CFP-10 secretion system of Mycobacterium marinum modulates phagosome maturation. Cell Microbiol. 8:1417-29
128. Gao LY, Guo S, McLaughlin B, Morisaki H, Engel JN, Brown EJ. 2004. A mycobacterial virulence gene cluster extending RD1 is required for cytolysis, bacterial spreading and ESAT-6 secretion. Mol. Microbiol. 53:1677-93
129. Mwandumba HC, Russell DG, Nyirenda MH, Anderson J, White SA, et al. 2004. Mycobacterium tuberculosis resides in nonacidified vacuoles in endocytically competent alveolar macrophages from patients with tuberculosis and HIV infection. J. Immunol. 172:4592-98
130. Wright GD. 2007. The antibiotic resistome: the nexus of chemical and genetic diversity. Nat. Rev. Microbiol. 5:175-86
131. McKinney JD. 2000. In vivo veritas: the search for TB drug targets goes live. Nat. Med. 6:1330-33
132. Minnikin D. 1982. Complex lipids: their chemistry, biosynthesis, and roles. In The Biology of Mycobacteria, ed. C Ratledge, J Stanford, pp. 94-184. London: Academic
133. Gokhale RS, Saxena P, Chopra T, Mohanty D. 2007. Versatile polyketide enzymatic machinery for the biosynthesis of complex mycobacterial lipids. Nat. Prod. Rep. 24:267-77